TNSN07294A1 - Treatment of metastasized tumors - Google Patents

Treatment of metastasized tumors

Info

Publication number
TNSN07294A1
TNSN07294A1 TNP2007000294A TNSN07294A TNSN07294A1 TN SN07294 A1 TNSN07294 A1 TN SN07294A1 TN P2007000294 A TNP2007000294 A TN P2007000294A TN SN07294 A TNSN07294 A TN SN07294A TN SN07294 A1 TNSN07294 A1 TN SN07294A1
Authority
TN
Tunisia
Prior art keywords
compound
tautomer
treatment
metastasized tumors
salt
Prior art date
Application number
TNP2007000294A
Other languages
English (en)
Inventor
De Menezes Daniel Lopes
Carla Heise
Xiaohua Xin
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36741085&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TNSN07294(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of TNSN07294A1 publication Critical patent/TNSN07294A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
TNP2007000294A 2005-01-27 2007-07-27 Treatment of metastasized tumors TNSN07294A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US64756805P 2005-01-27 2005-01-27
US66924505P 2005-04-06 2005-04-06
US72205305P 2005-09-29 2005-09-29
PCT/US2006/002979 WO2006081445A2 (en) 2005-01-27 2006-01-27 Treatment of metastasized tumors

Publications (1)

Publication Number Publication Date
TNSN07294A1 true TNSN07294A1 (en) 2008-12-31

Family

ID=36741085

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2007000294A TNSN07294A1 (en) 2005-01-27 2007-07-27 Treatment of metastasized tumors

Country Status (23)

Country Link
US (2) US20060183750A1 (es)
EP (2) EP2301546B1 (es)
JP (2) JP5371246B2 (es)
KR (1) KR101387985B1 (es)
CN (1) CN103893181A (es)
AT (1) ATE526025T1 (es)
AU (1) AU2006208012B2 (es)
BR (1) BRPI0607285A2 (es)
CA (1) CA2596084A1 (es)
CY (1) CY1112570T1 (es)
DK (1) DK1845990T3 (es)
ES (2) ES2374570T3 (es)
HK (1) HK1155664A1 (es)
IL (1) IL184866A0 (es)
MA (1) MA29266B1 (es)
MX (1) MX2007009099A (es)
NO (1) NO20074360L (es)
PL (2) PL1845990T3 (es)
PT (2) PT1845990E (es)
SG (1) SG173317A1 (es)
SI (1) SI2301546T1 (es)
TN (1) TNSN07294A1 (es)
WO (1) WO2006081445A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2334641T3 (es) 2000-09-01 2010-03-15 Novartis Vaccines And Diagnostics, Inc. Derivados aza heterociclicos y su uso terapeutico.
AU2003288899B2 (en) 2002-08-23 2009-09-03 Novartis Vaccines And Diagnostics, Inc. Benzimidazole quinolinones and uses thereof
MX2007014206A (es) * 2005-05-13 2008-02-07 Novartis Ag Metodos para tratar cancer resistente a los farmacos.
KR101368519B1 (ko) * 2005-05-23 2014-02-27 노파르티스 아게 결정형 및 기타 형태의 4-아미노-5-플루오로-3-［6-(4-메틸피페라진-1-일)-1ｈ-벤즈이미다졸-2-일］-1ｈ-퀴놀린-2-온 락트산염
AR070924A1 (es) * 2008-03-19 2010-05-12 Novartis Ag Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona
US20120064008A1 (en) * 2009-05-20 2012-03-15 Bruce Zetter Compositions for the treatment of metastatic cancer and methods of use thereof
PT2558095T (pt) * 2010-04-16 2019-01-29 Novartis Ag Composto orgânico para utilização no tratamento do cancro hepático
CN103547315A (zh) * 2011-05-19 2014-01-29 诺华股份有限公司 用于治疗腺样囊性癌的4-氨基-5-氟-3-[6-(4-甲基哌嗪-1-基)-1h-苯并咪唑-2-基]-1h-喹啉-2-酮
CN104093402A (zh) * 2012-01-31 2014-10-08 诺华股份有限公司 Rtk抑制剂与抗雌激素的组合及其治疗癌症的应用
CN109689649B (zh) * 2016-07-14 2022-07-19 百时美施贵宝公司 经二环杂芳基取代的化合物

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3663606A (en) * 1966-06-21 1972-05-16 Mitsui Toatsu Chemicals Organic imino-compounds
DE2363459A1 (de) 1973-12-20 1975-06-26 Basf Ag Neue fluoreszierende chinolinverbindungen
US4659657A (en) * 1982-12-24 1987-04-21 Bayer Aktiengesellschaft Chromogenic and fluorogenic esters for photometric or fluorimetric determination of phosphatases or sulphatases
US5073492A (en) * 1987-01-09 1991-12-17 The Johns Hopkins University Synergistic composition for endothelial cell growth
JPH0699497B2 (ja) 1987-04-16 1994-12-07 富士写真フイルム株式会社 光重合性組成物
DE3932953A1 (de) * 1989-10-03 1991-04-11 Boehringer Mannheim Gmbh Neue 2-bicyclo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB9108547D0 (en) 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
USRE37650E1 (en) * 1991-05-10 2002-04-09 Aventis Pharmacetical Products, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5856115A (en) * 1991-05-24 1999-01-05 Fred Hutchinson Cancer Research Center Assay for identification therapeutic agents
ATE239506T1 (de) * 1992-03-05 2003-05-15 Univ Texas Verwendung von immunokonjugate zur diagnose und/oder therapie der vaskularisierten tumoren
JP3142378B2 (ja) 1992-06-22 2001-03-07 ティーディーケイ株式会社 有機ｅｌ素子
US5763441A (en) * 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5981569A (en) * 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
US5792771A (en) * 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
JPH0743896A (ja) 1993-07-28 1995-02-14 Toyobo Co Ltd 光重合性組成物
JPH0829973A (ja) 1994-07-11 1996-02-02 Toyobo Co Ltd 光重合性組成物
JP3441246B2 (ja) * 1995-06-07 2003-08-25 富士写真フイルム株式会社 光重合性組成物
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE19610723A1 (de) 1996-03-19 1997-09-25 Bayer Ag Elektrolumineszierende Anordnungen unter Verwendung von Blendsystemen
US5942385A (en) * 1996-03-21 1999-08-24 Sugen, Inc. Method for molecular diagnosis of tumor angiogenesis and metastasis
CA2258728C (en) * 1996-06-19 2011-09-27 Rhone Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
BR9711805A (pt) 1996-06-20 2002-01-15 Regents The Univesity Of Texas Compostos e métodos para providenciar preparações farmacologicamente ativas e uso dos mesmos
US6111110A (en) * 1996-10-30 2000-08-29 Eli Lilly And Company Synthesis of benzo[f]quinolinones
TR200201051T2 (tr) * 1999-10-19 2002-09-23 Merck & Co., Inc. Tirosin kinaz inhibitörleri.
WO2001028993A2 (en) 1999-10-19 2001-04-26 Merck & Co. Inc. Tyrosine kinase inhibitors
WO2001062252A1 (en) 2000-02-25 2001-08-30 Merck & Co., Inc. Tyrosine kinase inhibitors
US6313138B1 (en) * 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
US6420382B2 (en) * 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1351946A2 (en) * 2000-09-01 2003-10-15 Icos Corporation Materials and methods to potentiate cancer treatment
ES2334641T3 (es) 2000-09-01 2010-03-15 Novartis Vaccines And Diagnostics, Inc. Derivados aza heterociclicos y su uso terapeutico.
US20030028018A1 (en) 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
ES2302106T3 (es) * 2000-09-11 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Procedimiento de preparacion de derivados de bencimidazol-2-il quinolina.
US7064215B2 (en) * 2001-07-03 2006-06-20 Chiron Corporation Indazole benzimidazole compounds
US7825132B2 (en) * 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
AU2003288899B2 (en) 2002-08-23 2009-09-03 Novartis Vaccines And Diagnostics, Inc. Benzimidazole quinolinones and uses thereof
EP1565187A4 (en) * 2002-11-13 2010-02-17 Novartis Vaccines & Diagnostic CANCER TREATMENT METHODS AND RELATED METHODS
US6774327B1 (en) * 2003-09-24 2004-08-10 Agilent Technologies, Inc. Hermetic seals for electronic components
JP4724665B2 (ja) * 2003-11-07 2011-07-13 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド キノリノン化合物を合成する方法
CA2556872C (en) * 2004-02-20 2015-05-12 Chiron Corporation Modulation of inflammatory and metastatic processes
BRPI0613200A2 (pt) * 2005-05-18 2012-01-03 M & G Polimeri Italia Spa composiÇço de poliÉster
KR102639757B1 (ko) 2017-01-09 2024-02-23 엘지이노텍 주식회사 카메라 모듈 및 이를 포함하는 광학기기

Also Published As

Publication number Publication date
AU2006208012A1 (en) 2006-08-03
EP1845990B1 (en) 2011-09-28
IL184866A0 (en) 2007-12-03
US20100173873A1 (en) 2010-07-08
DK1845990T3 (da) 2012-01-02
CY1112570T1 (el) 2016-02-10
NO20074360L (no) 2007-10-25
HK1155664A1 (en) 2012-05-25
CN103893181A (zh) 2014-07-02
KR20070118596A (ko) 2007-12-17
EP2301546B1 (en) 2014-09-10
EP1845990A2 (en) 2007-10-24
PT2301546E (pt) 2014-12-18
CA2596084A1 (en) 2006-08-03
PL2301546T3 (pl) 2015-03-31
MA29266B1 (fr) 2008-02-01
SI2301546T1 (sl) 2015-01-30
SG173317A1 (en) 2011-08-29
BRPI0607285A2 (pt) 2009-08-25
ATE526025T1 (de) 2011-10-15
ES2374570T3 (es) 2012-02-17
KR101387985B1 (ko) 2014-04-25
ES2525670T3 (es) 2014-12-29
JP2008528617A (ja) 2008-07-31
EP2301546A1 (en) 2011-03-30
JP2013177464A (ja) 2013-09-09
WO2006081445A2 (en) 2006-08-03
JP5371246B2 (ja) 2013-12-18
PL1845990T3 (pl) 2012-02-29
AU2006208012B2 (en) 2011-08-04
WO2006081445A3 (en) 2007-01-11
MX2007009099A (es) 2007-09-13
EP1845990A4 (en) 2008-04-30
US20060183750A1 (en) 2006-08-17
PT1845990E (pt) 2011-12-23

Similar Documents

Publication Publication Date Title
TNSN07294A1 (en) Treatment of metastasized tumors
MX2009009574A (es) Tratamiento de melanoma.
MX2007009649A (es) Derivados de meleimida, composiciones farmaceuticas y metodos para el tratamiento del cancer.
MX2007002398A (es) Nuevas composiciones farmaceuticas para el tratamiento de cancer.
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
MY191349A (en) New pharmaceutical compositions for the treatment of hyper-proliferative disorders
TW200700093A (en) Pharmaceutical composition for the treatment of cancer
WO2005110994A3 (en) Substituted pyrazolyl urea derivatives useful in the treatment of cancer
WO2008127594A3 (en) Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
WO2007038868A3 (en) Novel enediyne compound and uses thereof
WO2009067397A3 (en) Treatment for solid tumors
TNSN07419A1 (en) Methods for treating drug resistant cancer
WO2006044975A3 (en) Compositions and their use as anti-tumor agents
WO2005004808A3 (en) TETRACYCLIC COMPOUNDS AS c-MET INHIBITORS
WO2010121675A3 (en) Thiazolyl-benzimidazoles
TW200727904A (en) Method of administration for 5-(2-chlorophenyl)-1,2-dihydro-7-fluoro-8-methoxy-3-methyl-pyrazolo[3,4-b][1,4]benzodiazepine
EP1364652A4 (en) CURE FOR LUNG CANCER
WO2010014798A3 (en) Pyrimidotriazinediones and pyrimidopyrimidinediones and methods of using the same
GB0305928D0 (en) Organic compounds
UA98508C2 (ru) Иммуномодуляторное производное дипептида для лечения рака легких
WO2007017652A3 (en) Arylakylamines for the treatment of cancer
WO2014030142A3 (en) Nitroimidazole compounds and their use in cancer therapy
MY148385A (en) Maleimide derivatives, pharmaceutical compositions and methods for treatment of cancer
MY140324A (en) Maleimide derivatives, pharmaceutical compositions and methods for treatment of cancer